Abstract
Abstract. Poly ADP-Bibose polymerase (PARP) inhibitors have attracted wide attention as a new class of anticancer drugs. PARP inhibitors act by blocking PARP binding to sites of DNA damage, leading to failure of DNA repair and ultimately leading to apoptosis of tumor cells. In recent years, PARP inhibitors have achieved remarkable clinical results in a variety of cancer treatments, especially in BRCA mutation-associated breast and ovarian cancer treatments. The application of these PARP inhibitor drugs has significantly prolonged the survival of patients associated with BRCA mutations and improved the quality of life of patients. The limitations of PARP inhibitors are mainly manifested in two aspects: first, their specificity for PARP-1 is not high enough to lead to side effects after taking drugs; second, patients may develop resistance during long-term use of such drugs. In this paper, the mechanism of action of PARP inhibitors is reviewed, and deeply analyzed the chemical structure and efficacy of Olaparib, Niraparib and Rucaparib drugs, which provided a useful reference for subsequent clinical research and drug development.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call